Cell & Gene Therapy

What Cell & Gene Therapy does

BioInsights Publishing Ltd is a privately held UK digital publisher operating Cell & Gene Therapy Insights as the flagship of a four-title open-access, peer-reviewed journal portfolio covering advanced biotherapeutics. Founded with the journal in 2014 and headquartered at 44 Orange Row, Brighton, England & Wales (Company No. 9381574), the company publishes peer-reviewed commentary, original research, and expert analysis spanning cell and gene therapy, bioconjugates, nucleic acids, and vaccines, distributed globally via free registration on insights.bio. The product surface is a CMS-backed multi-journal publishing platform augmented by a podcast (The BioInsights Podcast, distributed on Apple Podcasts, Spotify, Amazon Music, and RSS), an expert-led webinar series, tech showcases ("Fast Facts"), and topic-organized content channels (Regulatory, Manufacturing, Analytics, Supply Chain, Business & Finance, etc.). A Special Interest Group (CGTI SIG) convenes academic and industry steering-committee members from institutions including Cabaletta Bio, Yale, Capstan Therapeutics, Allogene, Cleveland Clinic, Memorial Sloan Kettering, University of Pennsylvania, Fate Therapeutics, Vertex, and Kite (Gilead) to guide content priorities on immunotherapy and CAR-T.

The commercial model is two-sided. On the audience side, all journal content is free and open-access following self-serve registration, driving global readership across five functional personas — life-sciences researchers and developers, regulatory affairs professionals, manufacturing specialists, biopharma business leaders, and B2B marketing buyers at pharma and biotech companies. On the revenue side, the company sells sponsored content, custom content creation, webinars, roundtables, and thought-leadership packages to pharma, biotech, and life sciences marketing departments via direct B2B sales, with quote-based, individually negotiated pricing. Email newsletters, LinkedIn, and Twitter/X are the primary engagement and amplification channels, while podcast and webinar programming sit in the mid-funnel and support lead generation for the B2B partnership motion.

Operationally, BioInsights presents as a founder/operator-managed, single-HQ digital media business with no identified external institutional investment. Activity signals (a 2026 copyright, AACR 2026 post-event coverage, and continued publication across all four journals) indicate the platform is actively maintained and incrementally extended; no funding events, M&A, leadership changes, or major restructuring moves were disclosed in the available data, and the portfolio expansion to four journals plus the addition of an Immuno-oncology Insights navigation entry represents the primary observable growth vector.

Name

Cell & Gene Therapy

Legal name

BioInsights Publishing Ltd

Website

https://insights.bio

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

BioInsights Publishing Ltd operates Cell & Gene Therapy Insights as the flagship of a four-journal open-access portfolio covering cell/gene therapy, bioconjugates, nucleic acids, and vaccines, monetized through sponsored content and B2B marketing partnerships with pharma and biotech.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Sponsored Content and Webinars: Life sciences companies sponsor content including spotlights, webinars, and thought leadership articles. Sponsors can reach qualified professional audiences through branded content, with opt-in consent for data sharing.
2. B2B Content Marketing Services: Custom content creation, webinar production, and thought leadership article partnerships with pharma, biotech, and life sciences companies seeking to engage professional audiences.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Cell & Gene Therapy Insights is an open-access, peer-reviewed online journal focused on advances and innovation in cell and gene therapy R&D and manufacturing. It is one of four journals within BioInsights Publishing Ltd's content platform, delivering expert commentary, original research, and practical guidance from early discovery through clinical development and commercialization to life sciences researchers, developers, manufacturers, and business leaders globally. The journal is freely accessible after registration, with revenue generated through sponsored content, webinars, and B2B content marketing partnerships with pharma and biotech companies.

Product overview

BioInsights Publishing Ltd operates a multi-journal content platform focused on life sciences translation and commercialization, comprising four open-access peer-reviewed journals—Cell & Gene Therapy Insights, Vaccine Insights, Nucleic Acid Insights, and Bioconjugate Insights—alongside a podcast series (The BioInsights Podcast), webinar programming, and specialized content channels organized by topic area (including Business & Finance, Regulatory, Manufacturing, Analytics, and others). The company also hosts Special Interest Groups that convene steering committees of academic and industry experts for focused discussions on immunotherapy topics. All journal content is freely accessible following registration.

Differentiator

Problem solved

Functional benefit

Brands

• The BioInsights Podcast: Podcast series discussing the challenges of translating novel biologics from bench to clinic to market, featuring interviews with industry experts.

Products and services

• Cell & Gene Therapy Insights An open-access, peer-reviewed online journal focused on advances and innovation in cell and gene therapy R&D and manufacturing, delivering expert commentary, original research, and practical guidance from early discovery through clinical development and commercialization. Targeted at life sciences researchers, developers, manufacturers, and business leaders globally.
• Vaccine Insights An online, open-access, peer-reviewed journal focused on advances and innovation within vaccine R&D and manufacturing, covering discovery, immunology, preclinical and clinical development, pandemic preparedness, formulation, delivery, and manufacturing. Targeted at vaccine researchers, developers, manufacturers, and regulators.
• Nucleic Acid Insights A peer-reviewed journal covering news, trends, issues, and breakthroughs across the nucleic acids space including oligonucleotides, mRNA, DNA, formulation, and delivery, publishing original research, expert reviews, commentary, and clinical reports. Targeted at nucleic acid therapeutics researchers and developers.
• Bioconjugate Insights A peer-reviewed journal focused on advances in bioconjugate technologies, covering antibody-drug conjugates, nanozymes, tissue tropism, and responsive systems for targeted therapeutic and diagnostic delivery. Targeted at bioconjugate researchers and developers.
• The BioInsights Podcast A podcast series discussing the challenges of translating novel biologics from bench to clinic to market, featuring expert interviews on cell and gene therapy, ADCs, mRNA therapeutics, and nucleic acid innovations. 62+ episodes produced since 2022, distributed on Apple Podcasts, Spotify, and Amazon Music.
• BioInsights Webinars An expert-led webinar series providing discussions covering major developments, emerging technologies, and strategic considerations across advanced therapies, featuring industry experts and thought leaders. Offered to life sciences professionals free of charge, with sponsored webinar partnerships available to pharma and biotech companies.
• Tech Showcases (Fast Facts) Concise tech showcases providing focused technical content on specific products, technologies, or innovations in the cell and gene therapy space, available through the BioInsights platform as short-form sponsored content.

Quantifiable outcome

• 62+ podcast episodes produced since 2022

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Cabaletta BiocoreStrategic or Co-development PartnerGwendolyn Binder, President, Science and Technology at Cabaletta Bio, serves on the Cell & Gene Therapy Insights Special Interest Group Steering Committee, contributing strategic direction on immunotherapy topics and CAR-T cell therapy content.
• Yale University / Yale New Haven HospitalcoreStrategic or Co-development PartnerAlexey Bersenev, Assistant Professor & Lab Director at Yale University & Yale New Haven Hospital, serves on the CGTI SIG Steering Committee, providing expertise in clinical manufacturing of cellular products and GMP facility operations.
• Capstan TherapeuticscoreStrategic or Co-development PartnerAdrian Bot, Former CSO at Capstan Therapeutics, serves on the CGTI SIG Steering Committee, contributing expertise in cell therapy, gene therapy, and RNA-based precision medicines.
• Saisei Ventures / Sven Kili ConsultingcoreStrategic or Co-development PartnerSven Kili, Partner at Saisei Ventures and Principal at Sven Kili Consulting, serves on the CGTI SIG Steering Committee with expertise across all stages of CGT development, contributing strategic guidance on industry topics.
• Allogene TherapeuticscoreStrategic or Co-development PartnerBen Beneski, SVP & Chief Technical Officer at Allogene Therapeutics, participates as a confirmed member of the CGTI SIG, contributing expertise in allogeneic cell therapy manufacturing and development.
• Cleveland ClinicminorStrategic or Co-development PartnerJos Melenhorst, Vice Chair & Director at Cleveland Clinic Center for Immunotherapy & Precision Immuno-Oncology, participates in the CGTI SIG contributing expertise in immunotherapy and cell therapy research.
• Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerXiuyan Wang, Director of BioTherapeutics Core Facility at Memorial Sloan Kettering Cancer Center, participates in the CGTI SIG contributing expertise in cell therapy manufacturing and biobanking.
• University of PennsylvaniaminorStrategic or Co-development PartnerJanos Tanyi, Associate Professor at University of Pennsylvania Perelman School of Medicine, participates in CGTI SIG with expertise in cellular therapy research and solid tumor CAR-T development.
• Fate TherapeuticsminorStrategic or Co-development PartnerBobby Goulding from Fate Therapeutics participates in the CGTI SIG, contributing expertise in iPSC-derived cell therapy development.
• Vertex PharmaceuticalsminorStrategic or Co-development PartnerAshish Saksule, Associate Director at Vertex Pharmaceuticals Cell & Gene Therapy Process Development, participates in the CGTI SIG contributing expertise in process development for CGT.
• Kite (Gilead Company)minorStrategic or Co-development PartnerChris Johnson, Head of Product Quality & Life Cycle Management at Kite, participates in the CGTI SIG contributing expertise in CAR-T cell therapy product quality and commercialization.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Endpoints News: Endpoints News is a subscription-based biotech industry news outlet covering drug development, deals, and industry analysis. It is a direct peer in specialized biotech media with comparable target audience of biopharma executives and investors.
• Genetic Engineering & Biotechnology News (GEN): GEN is a long-standing life sciences trade publication covering biotech R&D, drug discovery, and bioprocessing. It is a direct peer as a B2B publisher serving the same advanced therapies and biopharma research audience.
• BioSpace: BioSpace is a leading life sciences industry news and career site serving biotech, pharma, and medical device professionals. It is a direct peer to BioInsights in the B2B life sciences media space, with comparable advertising- and content-driven monetization.
• BioCentury: BioCentury is a long-established subscription-based biotech industry analysis publisher serving investors, executives, and researchers. It is a direct peer in monetizing deep biopharma content for professional audiences.
• Fierce Biotech (Questex): Fierce Biotech is a flagship life sciences industry news brand owned by Questex, covering biotech R&D, clinical development, and industry trends. It is a direct peer in B2B life sciences media with a similar advertising-supported business model.
• Mary Ann Liebert: Mary Ann Liebert is a privately held specialty scientific publisher focused on peer-reviewed journals in biotechnology, medicine, and engineering. It is a direct peer as a smaller, independent scientific publisher competing in niche life sciences categories.

Broad incumbents

• Wiley: Wiley is a major scientific and scholarly publisher with a substantial life sciences journal portfolio. It is a broad incumbent in peer-reviewed life sciences publishing and competes for both authors and advertising/sponsorship revenue.
• Informa Pharma Intelligence: Informa Pharma Intelligence (Citeline, Pink Sheet, Trialtrove) is a major pharma intelligence and media platform owned by Informa. It is a broad incumbent in life sciences B2B media and intelligence, with substantially larger scale and advertiser relationships.
• Springer Nature: Springer Nature is one of the world's largest scientific publishers, with extensive life sciences journal portfolios including Nature-branded titles. It is a broad incumbent in peer-reviewed life sciences publishing with the resources to compete for the same audiences.

Emerging players

• Frontiers Media: Frontiers Media is an open-access scientific publisher that has rapidly grown its journal portfolio across life sciences. It is an emerging player that shares the open-access model with BioInsights and competes for the same translational research audience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/prof_chrismason
• LinkedInlinkedin.com/company/bioinsights

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell & Gene Therapy